CLINICAL & PIPELINE·Drug Approval
Rubicon Research's Generic Buspirone Hydrochloride Approval: A Deep Dive into Early Market Entry and Supply Chain Dynamics
Rubicon Research secured FDA approval for its Abbreviated New Drug Application (ANDA075521) for generic BUSPIRONE HYDROCHLORIDE tablets on April 5, 2002. This early market entry for the anxiolytic drug provided significant commercial advantage. The approval, covering multiple strengths, highlights strategic generic positioning and ongoing regulatory compliance, with Advagen Pharma Ltd. identified as a key manufacturing partner in the supply chain.
90-Day Activity